

زمانی میاسای ز آموختن  
اگر جان همی خواهی افروختن



# SOURCES OF PHARMACEUTICAL INFORMATION?

Hossein Karballaei Mirzahosseini  
Faculty of pharmacy





COMMENTARY · Volume 82, Issue 7, 6862, September 01, 2018

[Download Full Issue](#)

## It's Time to Confront Student Mental Health Issues Associated with Smartphones and Social Media

[Jeff Cain, EdD, MS](#)  

[Affiliations & Notes](#)  [Article Info](#) 

 [Download PDF](#)  [Cite](#)  [Share](#)  [Set Alert](#)  [Get Rights](#)  [Reprints](#)

[Previous article](#) [Next article](#)

### » Keywords

[smartphones](#) · [social media](#) · [mental health](#) · [anxiety](#) · [stress](#)

An increased focus on overall student health and wellness is one of the more recent evolutions in higher education. Pharmacy and other health professions colleges in particular have recognized that well-being is important for students preparing for high-stress health care careers. This awareness has prompted universities and colleges to proactively address risk factors for stress, depression and anxiety, and educate students about the importance of sleep, nutrition, exercise and hobbies.<sup>1</sup>



### Article metrics

31

Citations

193

Captures

2

55

# The Prevalence of Addiction to Social Network Among Students in Iran and its Factors Related: A Study Conducted in 2020

[Hoorieh Rahiminia](#)<sup>1,2</sup>, [Hamid Soori](#)<sup>1,3</sup>, [Mahdi Jafari](#)<sup>4,5</sup>, [Soheila Khodakarim](#)<sup>1,6,\*</sup>

► [Author information](#) ► [Article notes](#) ► [Copyright and License information](#)

PMCID: PMC8719277 PMID: [35136413](#)

Generally, 462 students (44%) had addiction to social networks, of which 449 (90.04%) had slight addiction and 13 (9.96%) had severe addiction

# SOCIAL MEDIA ADDICTION



ما ده این رنبد گندم می کنیم

گندم جمع آنده کم می کنیم


اول ای جان دفع شرموش کن

واگهان ده جمع گندم کوش کن



# SCIMAGO RESEARCH CENTERS RANKING


- The ranking spans 391 research centers representing the **22** countries in the MENA region. It examines 16 indicators from 3 dimensions (Research, Innovation and Society).
- Journal Ranks
- Country Ranks
- Viz Tools





# THE RANKING OF BEST JOURNALS FOR MEDICINE



Research.com

Rank	Journal Details		Best Scientists	Documents	Impact Score
1	 ELSEVIER	<b>The Lancet</b> 0140-6736	3337	2497	172.30
2	 MASSACHUSETTS MEDICAL SOCIETY	<b>New England Journal of Medicine</b> 0028-4793	3269	3507	163.20
3	 Springer	<b>Nature Medicine</b> 1078-8956	2131	1203	91.10
4	 ELSEVIER	<b>The Lancet Oncology</b> 1470-2045	1541	1195	79.60
5	 ASCO	<b>Journal of Clinical Oncology</b> 0732-183X	3535	16668	79.30



ARTICLES · [Online first](#), November 25, 2024

## Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

[Prof Sunil V Badve, PhD](#) <sup>a,b,c</sup>  · [Anika Bilal, MD](#)<sup>d</sup> · [Matthew M Y Lee, PhD](#)<sup>e</sup> · [Prof Naveed Sattar, MD](#)<sup>e</sup> · [Prof Hertzel C Gerstein, MD](#)<sup>f</sup> · [Prof Christian T Ruff, MD MPH](#)<sup>g</sup> et al. [Show more](#)

[Affiliations & Notes](#)  [Article Info](#)  [Linked Articles \(1\)](#) 

## THE LANCET Diabetes & Endocrinology



Get Access



Cite



Share



Set Alert



Get Rights



Reprints



How Outline

### Interpretation

We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.

## Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

[Qingyang Shi, MM](#)<sup>a,†</sup> · [Yang Wang, MB](#)<sup>a,†</sup> · [Qiukui Hao, MD](#)<sup>b,h</sup> · [Prof Per Olav Vandvik, MD](#)<sup>i</sup> · [Prof Gordon Guyatt, MD](#)<sup>h</sup> · [Jing Li, MD](#)<sup>a</sup> et al. [Show more](#)

[Affiliations & Notes](#)  [Article Info](#)  [Linked Articles \(1\)](#) 

### Interpretation

In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective.

ARTICLES · [Online first](#), 102920, November 14, 2024 · *Open Access*

## Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review


[Mohsan Subhani](#)<sup>a,b,m</sup>  · [Ashwin Dhanda](#)<sup>c,m</sup> · [James A. King](#)<sup>d,e,m</sup> · [Fiona C. Warren](#)<sup>f</sup> · [Siobhan Creanor](#)<sup>f</sup> · [Melanie J. Davies](#)<sup>e,g</sup> et al. [Show more](#)

[Affiliations & Notes](#)  [Article Info](#) 

### Interpretation

There is little high-quality evidence demonstrating the effect of GLP-1 RAs on alcohol use. Subgroup analysis from two RCTs and supporting data from four observational studies suggest that GLP-1 RAs may reduce alcohol consumption and improve outcomes in some individuals. Heterogeneous study findings warrant further research to establish the effectiveness and safety of GLP-1 RAs in this population.

# BRAIN'S REWARD SYSTEM





> View all Commissions



## Browse

### Journals

[The Lancet](#)

[The Lancet Child & Adolescent Health](#)

[The Lancet Diabetes & Endocrinology](#)

[The Lancet Digital Health](#)

[The Lancet Gastroenterology & Hepatology](#)

[The Lancet Global Health](#)

[The Lancet Haematology](#)

[The Lancet Healthy Longevity](#)

[The Lancet HIV](#)

[The Lancet Infectious Diseases](#)

[The Lancet Microbe](#)

[The Lancet Neurology](#)

[The Lancet Oncology](#)

[The Lancet Planetary Health](#)

[The Lancet Psychiatry](#)

[The Lancet Public Health](#)

[The Lancet Regional Health – Americas](#)

[The Lancet Regional Health – Europe](#)

[The Lancet Regional Health – Southeast Asia](#)



[The Lancet Regional Health – Western Pacific](#)

[The Lancet Respiratory Medicine](#)

[The Lancet Rheumatology](#)

[eBioMedicine](#)

[eClinicalMedicine](#)

Rank	Journal Details		Best Scientists	Documents	Impact Score
6		<b>JAMA - Journal of the American Medical Association</b> 0098-7484	2165	2295	77.50
7		<b>European Heart Journal</b> 0195-668X	2328	10259	74.90
8		<b>The Lancet Neurology</b> 1474-4422	1041	717	68.80
9		<b>Circulation</b> 0009-7322	2960	9999	68.30
10		<b>Journal of the American College of Cardiology</b> 0735-1097	2299	9432	67.50

# JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

JAMA Network

JAMA®

Search All ▾ Enter Search Term 🔍


Sign In ▾

# JAMA®

[Home](#)[New Online](#)[Issues](#)[For Authors](#)

## Editor's Choice: Trends in Medical School Enrollment

Advertisement



*Original Investigation*  
**Association of Severe Maternal Morbidity With Subsequent Birth**  
Eleni Tsamantioti, MD, MMedSc; Anna Sandström, MD, PhD; Charlotte Lindblad Wollmann, MD, PhD; et al

*Editorial*  
**Severe Maternal Morbidity and Subsequent Birth—Understanding and Informing a Woman's Choice**  
Anders Husby, MD, PhD; Heather A. Boyd, PhD

Get the latest from JAMA

Email address  [Sign Up](#)

[Privacy Policy](#) | [Terms of Use](#)

[f](#) [X](#) [@](#) [in](#) [v](#) [p](#) [RSS](#) [📶](#)

# JAMA

## JOURNALS

- JAMA<sup>®</sup>
- JAMA Network Open
- JAMA Cardiology
- JAMA Dermatology
- JAMA Health Forum
- JAMA Internal Medicine
- JAMA Neurology
- JAMA Oncology
- JAMA Ophthalmology
- JAMA Otolaryngology-Head & Neck Surgery

JAMA Pediatrics

JAMA Psychiatry

JAMA Surgery

Archives of Neurology & Psychiatry (1919-1959)

## PODCASTS

Clinical Reviews

Editors' Summary

Medical News

Author Interviews

More





## Original Investigation

November 18, 2024

# Antidiabetic Medication and Asthma Attacks

Bohee Lee, PhD<sup>1</sup>; Kenneth K. C. Man, PhD<sup>2</sup>; Ernie Wong, MD<sup>1</sup>; [et al](#)

» [Author Affiliations](#)

*JAMA Intern Med.* Published online November 18, 2024. doi:10.1001/jamainternmed.2024.5982

**Meaning** The study results suggest that metformin was associated with a significant lowering of asthma attacks and the addition of glucagon-like peptide-1 receptor agonists was associated with a synergistic additive effect.

November 20, 2024

# Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk

Xavier Sendaydiego, MD<sup>1</sup>; Laura S. Gold, PhD<sup>2,3</sup>; Maureen Dubreuil, MD, MSc<sup>4,5</sup>; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

*JAMA Netw Open.* 2024;7(11):e2446336. doi:10.1001/jamanetworkopen.2024.46336

**Findings** In this cohort study consisting of 25 305 individuals who initiated treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs, a statistically significantly higher risk of incident cancer was seen with rituximab, abatacept, and JAKis compared with TNFis. Individuals initiating rituximab likely had a higher risk of incident cancer due to channeling bias, rather than the drug itself increasing cancer risk.

**Original Investigation** | Pharmacy and Clinical Pharmacology

January 4, 2024

# Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes

Rachel Dankner, MD, MPH<sup>1,2</sup>; Havi Murad, PhD<sup>3</sup>; Nirit Agay, PhD<sup>1,3</sup>; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

*JAMA Netw Open.* 2024;7(1):e2350408. doi:10.1001/jamanetworkopen.2023.50408

**Findings** In this cohort study of 543 595 patients, compared with treatment with basal insulin, treatment of comparable patients with type 2 diabetes with GLP-1RA was not associated with excess risk of pancreatic cancer.

## Original Investigation

October 21, 2024

# Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor-Inhibitor Treatment for Autoimmune Diseases A Systematic Review and Meta-Analysis

Wenhui Xie, PhD<sup>1,2</sup>; Yunchuang Sun, MD<sup>3</sup>; Wei Zhang, MD<sup>4</sup>; [et al](#)

**Findings** This systematic review and meta-analysis of 18 studies including more than 1 million patients with autoimmune diseases revealed that exposure to TNF inhibitors was associated with 36% increased risk of inflammatory CNS diseases, especially demyelinating diseases. The risk of inflammatory CNS events following anti-TNF therapy did not differ by types of autoimmune diseases or prescribed TNF inhibitors.



## Original Investigation

September 30, 2024

# Antiseizure Medications and Cardiovascular Events in Older People With Epilepsy

Jimmy Li, MD<sup>1,2</sup>; Nathan A. Shlobin, MD<sup>3</sup>; Roland D. Thijs, MD, PhD<sup>4,5,6</sup>; [et al](#)

» [Author Affiliations](#)

*JAMA Neurol.* 2024;81(11):1178-1186. doi:10.1001/jamaneurol.2024.3210

**Findings** This cohort study included 27 230 individuals and, using the Canadian Longitudinal Study on Aging, found that adults with a lifetime history of epilepsy were approximately 2 times more likely to report new CVEs, including strokes, transient ischemic attacks, and myocardial infarctions, over 6 years. Almost one-third of this association may result from EIASM use.

Original Investigation | Nephrology

August 20, 2024

# Sacubitril-Valsartan in Patients Requiring Hemodialysis

Dustin Le, MD, MHS<sup>1</sup>; Morgan E. Grams, MD, PhD<sup>2</sup>; Josef Coresh, MD, PhD<sup>3</sup>; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

*JAMA Netw Open.* 2024;7(8):e2429237. doi:10.1001/jamanetworkopen.2024.29237

**Findings** In this comparative effectiveness research study of 1434 patient pairs, initiation of sacubitril-valsartan therapy was associated with a statistically significant 18% reduction in all-cause mortality and 14% reduction in all-cause hospitalization.

March 19, 2024

# Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis

## A Randomized Clinical Trial

Tracey G. Simon, MD, MPH<sup>1,2,3</sup>; Robert M. Wilechansky, MD<sup>1,2,4</sup>; Stefania Stoyanova, BA<sup>4</sup>; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

*JAMA*. 2024;331(11):920-929. doi:10.1001/jama.2024.1215

**Conclusions and Relevance** In this preliminary randomized clinical trial of patients with MASLD, 6 months of daily low-dose aspirin significantly reduced hepatic fat quantity compared with placebo. Further study in a larger sample size is necessary to confirm these findings.

April 15, 2024

# Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban

Wayne A. Ray, PhD<sup>1</sup>; Cecilia P. Chung, MD, MPH<sup>2,3</sup>; C. Michael Stein, MB, ChB<sup>4,5</sup>; [et al](#)

» [Author Affiliations](#) | [Article Information](#)

JAMA. 2024;331(18):1565-1575. doi:10.1001/jama.2024.3867

**Findings** In this cohort study of 204155 patients aged 65 years or older, those treated with diltiazem had a significantly greater risk of serious bleeding compared with those treated with metoprolol.

**Conclusions and Relevance** In Medicare patients with atrial fibrillation receiving apixaban or rivaroxaban, diltiazem was associated with greater risk of serious bleeding than metoprolol, particularly for diltiazem doses exceeding 120 mg/d.





The NEW ENGLAND  
JOURNAL of MEDICINE

[SPECIALTIES](#) ▾

[TOPICS](#) ▾

[MULTIMEDIA](#) ▾

[CURRENT ISSUE](#) ▾

[LEARNING/CME](#) ▾

[AUTHOR CENTER](#)

[PUBLICATIONS](#) ▾

ORIGINAL ARTICLE



# Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections

**Author:** The BALANCE Investigators, for the Canadian Critical Care Trials Group, the Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, the Australian and New Zealand Intensive Care Society Clinical Trials Group, and the Australasian Society for Infectious Diseases Clinical Research Network\* [Author Info & Affiliations](#)



Published November 20, 2024 | DOI: 10.1056/NEJMoa2404991 | [Copyright © 2024](#)



ORIGINAL ARTICLE



# Routine Spironolactone in Acute Myocardial Infarction

**Authors:** Sanjit S. Jolly, M.D. , Marc-André d'Entremont, M.D., M.P.H., Bertram Pitt, M.D., Shun Fu Lee, Ph.D., Rajibul Mian, Ph.D., Jessica Tyrwhitt, B.Sc., Sasko Kedev, M.D., Ph.D., , for the CLEAR investigators\* [Author Info & Affiliations](#)

Published November 17, 2024 | DOI: 10.1056/NEJMoa2405923 | [Copyright © 2024](#)

## RESULTS

We enrolled 7062 patients at 104 centers in 14 countries; 3537 patients were assigned to receive spironolactone and 3525 to receive placebo. At the time of our analyses, the vital status was unknown for 45 patients (0.6%). For the first primary outcome, there were 183 events (1.7 per 100 patient-years) in the spironolactone group as compared with 220 events (2.1 per 100 patient-years) in the placebo group over a median follow-up period of 3 years (hazard ratio adjusted for competing risk of death from noncardiovascular causes, 0.91; 95% confidence interval [CI], 0.69 to 1.21;  $P=0.51$ ). With respect to the second primary outcome, an event occurred in 280 of 3537 patients (7.9%) in the spironolactone group and 294 of 3525 patients (8.3%) in the placebo group (hazard ratio adjusted for competing risk, 0.96; 95% CI, 0.81 to 1.13;  $P=0.60$ ). Serious adverse events were reported in 255 patients (7.2%) in the spironolactone group and 241 (6.8%) in the placebo group.



The NEW ENGLAND  
JOURNAL of MEDICINE

SPECIALTIES ▾

TOPICS ▾

MULTIMEDIA ▾

CURRENT ISSUE ▾

LEARNING/CME ▾

AUTHOR CENTER


PUBLICATIONS ▾



VIDEOS IN CLINICAL MEDICINE



# Epidural Glucocorticoid Injection for Lumbosacral Radicular Pain

**Authors:** David Hao, M.D. , R. Jason Yong, M.D., Samer Narouze, M.D., Alexandra E. Fogarty, M.D., Olivia M. Sutton, M.D., and Milan P. Stojanovic, M.D. [Author Info & Affiliations](#)

Published November 6, 2024 | N Engl J Med 2024;391: e38 | DOI: 10.1056/NEJMvcm2313448 | [VOL. 391 NO. 18](#)



Copyright © 2024



ORIGINAL ARTICLE



# A Randomized Trial of Intravenous Amino Acids for Kidney Protection

**Authors:** Giovanni Landoni, M.D., Fabrizio Monaco, M.D., Lian Kah Ti, M.B., B.S., M.Med., Martina Baiardo Redaelli, M.D., Nikola Bradic, M.D., Marco Comis, M.D., Yuki Kotani, M.D. , , for the PROTECTION Study Group\* [Author Info & Affiliations](#)

Published June 12, 2024 | N Engl J Med 2024;391:687-698 | DOI: 10.1056/NEJMoa2403769 | **VOL. 391 NO. 8**

**Copyright © 2024**

## CONCLUSIONS

Among adult patients undergoing cardiac surgery, infusion of amino acids reduced the occurrence of AKI. (Funded by the Italian Ministry of Health; PROTECTION ClinicalTrials.gov number, [NCT03709264](#).)

[nature](#) > [news](#) > article

**NEWS** | 26 September 2024

# Stem cells reverse woman's diabetes — a world first

**Patient is the first person with type 1 diabetes to receive this kind of transplant.**

[nature](#) > [nature medicine](#) > [news feature](#) > article

News Feature | Published: 04 September 2024

## Hibernation science harnessed to treat obesity and modify metabolism

[Carrie Arnold](#)

[Nature Medicine](#) **30**, 2700–2703 (2024) | [Cite this article](#)

**2447** Accesses | **16** Altmetric | [Metrics](#)

**By understanding the biology of hibernating animals, scientists are developing new treatments to trigger weight loss and alter metabolic pathways.**



# HIBERNATION



[nature](#) > [nature medicine](#) > [brief communications](#) > article

Brief Communication | [Open access](#) | Published: 25 July 2024

## The recombinant shingles vaccine is associated with lower risk of dementia

[Maxime Taquet](#) , [Quentin Dercon](#), [John A. Todd](#) & [Paul J. Harrison](#) 

[Nature Medicine](#) **30**, 2777–2781 (2024) | [Cite this article](#)

**42k** Accesses | **4** Citations | **3025** Altmetric | [Metrics](#)

[nature](#) > [nature medicine](#) > [editorials](#) > article

Editorial | Published: 19 April 2024

## Microplastics are everywhere – we need to understand how they affect human health

[Nature Medicine](#) **30**, 913 (2024) | [Cite this article](#)

**39k** Accesses | **6** Citations | **899** Altmetric | [Metrics](#)

**As evidence emerges describing the accumulation of small plastic particles in various organs and tissues of the body, a much deeper understanding of the effects of these particles on human health is urgently needed.**

# MICROPLASTICS ARE EVERYWHERE

در نمونه‌های پلاک‌های آترواسکلروتیک که با جراحی از شریان‌های کاروتید 304 نفر جدا شده بودند، پلاستیک در پلاک‌های تقریباً نیمی از این گروه، با پلی اتیلن در 150 نمونه و پلی وینیل کلرید در 31 مورد شناسایی شد.



Explore content ▾

About the journal ▾

Publish with us ▾

Subscribe

[nature](#) > [nature reviews drug discovery](#) > [news in brief](#) > article









NEWS IN BRIEF | 26 September 2024 | Update [27 September 2024](#)

# FDA approves first schizophrenia drug with new mechanism of action since 1950s

By [Katie Kingwell](#)



Sign up to N

	Title	Type	↓ SJR	H index	Total Docs. (2023)	Total Docs. (3years)	Total Refs. (2023)	Total Cites (3years)	Citable Docs. (3years)	Cites / Doc. (2years)	F
1	<a href="#">American Journal of Pharmaceutical Education</a> 	journal	1.110 	78	279	494	3042	1263	404	1.74	
2	<a href="#">Journal of Pharmaceutical Analysis</a> 	journal	1.068 	51	121	247	9301	1852	245	6.09	
3	<a href="#">Research in Social and Administrative Pharmacy</a>	journal	0.833 	69	167	747	8486	2511	621	3.79	
4	<a href="#">Journal of managed care &amp; specialty pharmacy</a>	journal	0.766 	75	149	549	4254	1052	493	2.09	
5	<a href="#">Journal of Pharmaceutical Policy and Practice</a> 	journal	0.740 	32	165	291	6518	936	256	2.71	
6	<a href="#">Journal of the American Pharmacists Association : JAPhA</a>	journal	0.593 	73	266	803	7419	1409	658	1.83	
7	<a href="#">International Journal of Clinical Pharmacy</a>	journal	0.577 	71	163	513	6171	1192	464	2.30	



Rank	Journal	Impact Factor
1	Nature Reviews Drug Discovery	ca. 122.7
2	Pharmacological Reviews	ca. 19.3
3	Drug Resistance Updates	ca. 15.8
4	Advanced Drug Delivery Reviews	ca. 15.2
5	Acta Pharmaceutica Sinica B	ca. 14.7
6	Trends in Pharmacological Sciences	ca. 13.9
7	Drugs	ca. 13
8	Pharmacology & Therapeutics	ca. 12
9	Annual Review of Pharmacology and Toxicology	ca. 11.2
10	Medicinal Research Reviews	ca. 10.9
11	Asian Journal of Pharmaceutical Sciences	ca. 10.7
12	Journal of Controlled Release	ca. 10.5
13	Pharmacological Research	ca. 9.1
14	Journal of Clinical Pharmacy and Therapeutics	ca. 8.4

	Publication	<u>h5-index</u>	<u>h5-median</u>
1.	Nature Reviews Drug Discovery	<u>136</u>	324
2.	Frontiers in Pharmacology	<u>133</u>	184
3.	Journal of controlled release	<u>125</u>	172
4.	Advanced Drug Delivery Reviews	<u>113</u>	174
5.	Pharmacological Research	<u>113</u>	149
6.	Journal of Medicinal Chemistry	<u>112</u>	165
7.	Pharmaceutics	<u>111</u>	153
8.	Pharmacology & Therapeutics	<u>99</u>	139
9.	International Journal of Nanomedicine	<u>99</u>	138
10.	International Journal of Pharmaceutics	<u>99</u>	128
11.	Acta Pharmaceutica Sinica B	<u>96</u>	152
12.	Drugs	<u>94</u>	141
13.	Membranes	<u>93</u>	111

[nature](#) > [nature reviews drug discovery](#) > [review articles](#) > [article](#)

Review Article | Published: 11 September 2024

# Targeting cytokine networks in neuroinflammatory diseases

[Burkhard Becher](#) , [Tobias Derfuss](#)  & [Roland Liblau](#) 

[Nature Reviews Drug Discovery](#) **23**, 862–879 (2024) | [Cite this article](#)

**3848** Accesses | **26** Altmetric | [Metrics](#)

## Abstract

**Sections**

[Figures](#)

[References](#)

[Abstract](#)

[References](#)

[Acknowledgements](#)

# Frontiers in Pharmacology

4.4

Impact Factor

7.8

CiteScore

356,000

Citations

[Submit](#) →

## Community driven journals

Join our editorial board and collaborate with a team of independent researchers from around the world, carefully selected for their field expertise.

[Editorial board](#) >



# Advanced Drug Delivery Reviews

Supports open access

28.1

CiteScore

15.2

Impact Factor

[Articles & Issues](#) ▼

[About](#) ▼

[Publish](#) ▼

[Order journal](#) ↗



[Search in this journal](#)

[Submit your article](#) ↗

[Guide for authors](#)

## About the journal

The aim of the Journal is to provide a forum for the critical analysis of advanced **drug** and **gene delivery** systems and their applications in **human** and **veterinary medicine**. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to ...

[View full aims & scope](#)



Access through your organization

Purchase PDF

Patient Access



ELSEVIER

## Advanced Drug Delivery Reviews

Available online 17 November 2024, 115473

In Press, Journal Pre-proof [What's this?](#)



# DRUG DELIVERY SYSTEMS FOR TREATING NEURODEVELOPMENTAL DISORDERS

Boaz Barak<sup>a, b</sup>, Paolo Decuzzi<sup>c, d</sup>

[Show more](#)

Part of special issue

[An integrated perspective for the  
diagnosis and therapy in  
neurodevelopmental disorders](#)

Edited by Paolo Decuzzi, Boaz Barak,

Commissioned by Maria J. Vicent



[View special issue](#)

Recommended articles